Back to Agenda
European Medicines Agencies Network Strategy to 2028: Spotlight on Innovation, Availability & Shortages of Medicines
Session Chair(s)
Melanie Carr
Head of Stakeholders and Communication Division, European Medicines Agency, Netherlands
Aimad Torqui
Head of Division European cooperation and veterinary affairs , MEB, Netherlands
This DIAmond session will update on the status of implementation of the European Medicines Agencies Network Strategy 2025 so far and provide an outlook to 2028 in the areas of innovation, availability of medicines.
Participants will hear from EMA and HMA on the state of play and planned future activities in these two areas, and gain insights on the perspective and expectation of stakeholders including academia, patient representatives and industry.
Speaker(s)
Falk Ehmann, MD, PHD, MS
Head of Innovation and Development Accelerator, Regulatory Science and Innovation Task Force, European Medicines Agency, Netherlands
State of Play of the Strategy with Focus on Innovation
Maria Lamas Diaz
Evecutive Director, AEMPS, Spain
State of Play of the Strategy with Focus on Innovation
Monica Dias, PHARMD, PHD, MPHARM, RPH
Head of Supply and Availability of Medicines and Devices, a.i., European Medicines Agency, Netherlands
State of Play of the Strategy with Focus on Availability of Medicines
Bjorn Eriksson
, Medical Products Agency, Sweden
François Houyez
Treatment Information and Access Director, Health Policy Advisor, European Organisation for Rare Diseases (EURORDIS), France
Panelist
Hubert Leufkens, PHARMD, PHD
Emeritus Professor of Pharmaceutical Policy and Regulatory Science, Utrecht University, Netherlands
Panelist
Nathalie Moll
Director General, European Federation of Pharmaceutical Industries and Associations (EFPIA), Belgium
Panelist
Adrian van den Hoven
Director General, Medicines for Europe, Belgium
Panelist
Have an account?